Reuters logo
2 months ago
BRIEF-PTC Therapeutics announces FDA advisory committee meeting for Ataluren for treatment of nonsense mutation dystrophinopathy
June 6, 2017 / 12:21 PM / 2 months ago

BRIEF-PTC Therapeutics announces FDA advisory committee meeting for Ataluren for treatment of nonsense mutation dystrophinopathy

June 6 (Reuters) - PTC Therapeutics Inc:

* PTC Therapeutics announces FDA advisory committee meeting for Ataluren for the treatment of nonsense mutation dystrophinopathy

* Says September 28th is FDA's tentative date for advisory committee meeting

* Says FDA set a PDUFA goal date of October 24, 2017 for completion of its review of Ataluren NDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below